Clinical Trial Update: Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries

View source ↗

Summary

The update presents the results of a study evaluating how effective Eliquis risk minimization tools are in European Economic Area countries.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Venous Thromboembolism

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Stroke, Systemic Embolism, VTEt and VTEp | Status: COMPLETED